Vivos Therapeutics Price/Book Ratio 2020-2025 | VVOS

Vivos Therapeutics price/book ratio from 2020 to 2025. Price/book ratio can be defined as

Vivos Therapeutics Price/Book Ratio 2020-2025 | VVOS

Vivos Therapeutics price/book ratio from 2020 to 2025. Price/book ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.9B
Zoetis (ZTS)$67.3B
Takeda Pharmaceutical (TAK)$46.3B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$32.4B
Sandoz Group AG (SDZNY)$25.8B
Summit Therapeutics (SMMT)$19.7B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.4B
Corcept Therapeutics (CORT)$7.3B
Madrigal Pharmaceuticals (MDGL)$7B
Ionis Pharmaceuticals (IONS)$6.7B
Grifols, S.A (GRFS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Procaps Group, S.A (PROCF)$3.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B